Viewing Study NCT02512133


Ignite Creation Date: 2025-12-25 @ 3:01 AM
Ignite Modification Date: 2026-03-09 @ 7:50 AM
Study NCT ID: NCT02512133
Status: UNKNOWN
Last Update Posted: 2015-07-30
First Post: 2015-07-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: MIGS VS SLT Comparison in Glaucoma Patients
Sponsor: University of Turin, Italy
Organization:

Study Overview

Official Title: MIGS VS SLT in Glaucoma Patients: Prospective Study
Status: UNKNOWN
Status Verified Date: 2015-07
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To compare the intraocular pressure (IOP) and number of glaucoma medications lowering of microinvasive glaucoma surgery (MIGS) with the implantation of the trabecular device Hydrus (Ivantis) as a solo procedure and 360° selective laser trabeculoplasty (SLT) to treat primary open angle glaucoma (POAG).
Detailed Description: Eligible study patients diagnosed with POAG and not sufficiently controlled by, intolerant of, or non-compliant with their current IOP-lowering regimen. Patients with IOP\>21 mm Hg upon at least two consecutive measurements. Study subjects with typical glaucomatous visual field (VF) loss on Octopus or Humphrey automated perimetry (Carl Zeiss Meditec, Dublin, CA) and glaucomatous alterations to the optic nerve head. Visual field classified as glaucomatous according to the European Glaucoma Society guidelines.

Exclusion criteria : eye surgery in the previous 6 months, any previous surgery for glaucoma, evidence of glaucoma of a type other than POAG, and medication with systemic or topical steroids.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: